NCT03133221View on ClinicalTrials.gov

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 23, 2017

Primary Completion Date

June 15, 2023

Study Completion Date

September 29, 2024

Conditions
Non Hodgkin LymphomaFollicular LymphomaIndolent LymphomaB-cell LymphomaTransformed LymphomaMarginal Zone LymphomaWaldenstrom MacroglobulinemiaSmall Lymphocytic LymphomaLymphoplasmacytic Lymphoma
Interventions
DRUG

Zydelig

Zydelig given at 150mg continuously in 28-day cycles

Trial Locations (3)

33136

University of Miami Sylvester Comprehensive Cancer Center, Miami

53226

Medical College of Wisconsin, Milwaukee

21201-1592

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

collaborator

University of Miami Sylvester Comprehensive Cancer Center

OTHER

lead

University of Maryland, Baltimore

OTHER